Metabolic Adaptation to Chronic Inhibition of Mitochondrial Protein Synthesis in Acute Myeloid Leukemia Cells

Bozhena Jhas, Shrivani Sriskanthadevan, Marko Škrtić, Mahadeo A. Sukhai, Véronique Voisin, Yulia Jitkova, Marcela Gronda, Rose Hurren, Rob C. Laister, Gary D. Bader, Mark D. Minden, Aaron D. SchimmerPLoS 2013 · DOI

Abstract

Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in leukemia cells through the inhibition of mitochondrial protein synthesis. Here, we sought to understand mechanisms of resistance to tigecycline by establishing a leukemia cell line resistant to the drug. TEX leukemia cells were treated with increasing concentrations of tigecycline over 4 months and a population of cells resistant to tigecycline (RTEX+TIG) was selected. Compared to wild type cells, RTEX+TIG cells had undetectable levels of mitochondrially translated proteins Cox-1 and Cox-2, reduced oxygen consumption and increased rates of glycolysis. Moreover, RTEX+TIG cells were more sensitive to inhibitors of glycolysis and more resistant to hypoxia. By electron microscopy, RTEX+TIG cells had abnormally swollen mitochondria with irregular cristae structures. RNA sequencing demonstrated a significant over-representation of genes with binding sites for the HIF1α:HIF1β transcription factor complex in their promoters. Upregulation of HIF1α mRNA and protein in RTEX+TIG cells was confirmed by Q-RTPCR and immunoblotting. Strikingly, upon removal of tigecycline from RTEX+TIG cells, the cells re-established aerobic metabolism. Levels of Cox-1 and Cox-2, oxygen consumption, glycolysis, mitochondrial mass and mitochondrial membrane potential returned to wild type levels, but HIF1α remained elevated. However, upon re-treatment with tigecycline for 72 hours, the glycolytic phenotype was re-established. Thus, we have generated cells with a reversible metabolic phenotype by chronic treatment with an inhibitor of mitochondrial protein synthesis. These cells will provide insight into cellular adaptations used to cope with metabolic stress.

Introduction

Acute Myeloid Leukemia (AML) cells often exhibit a high dependency on mitochondrial function for survival. Recent studies identified the antibiotic tigecycline as a potent anti-leukemic agent due to its ability to inhibit mitochondrial protein synthesis. While effective, the emergence of resistance remains a significant clinical challenge. This study investigates the adaptive mechanisms AML cells employ to survive chronic mitochondrial inhibition, specifically focusing on whether resistance is a permanent genetic change or a flexible, reversible metabolic adaptation.

Materials and Methods

The human leukemia cell line TEX was used as the parental model. A resistant population, RTEX+TIG, was generated by exposing TEX cells to escalating concentrations of tigecycline over a four-month period.

Characterization of the resistant phenotype involved:

  • Metabolic Flux Analysis: Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR) were measured using Seahorse XF96 analyzers to assess oxidative phosphorylation and glycolysis.
  • Imaging: Transmission Electron Microscopy (TEM) was employed to visualize changes in mitochondrial ultrastructure.
  • Transcriptomics: RNA-sequencing followed by Gene Set Enrichment Analysis (GSEA) and promoter analysis (oPOSSUM v3.0) identified key regulatory pathways.
  • Reversibility Studies: The drug was removed for seven days to evaluate the stability of the resistant phenotype and potential for metabolic recovery.

Results

Development of Resistance and Cross-Resistance

Chronic treatment with tigecycline successfully produced a resistant cell line. RTEX+TIG cells exhibited significantly higher viability compared to parental TEX cells when exposed to tigecycline, with an $IC_{50}$ exceeding 24 µM (compared to 2.8 µM for TEX). Interestingly, these cells also showed cross-resistance to chloramphenicol, another inhibitor of mitochondrial protein synthesis, suggesting a common mechanism of adaptation. Importantly, the resistance was not due to decreased drug uptake, as intracellular tigecycline levels were comparable between the two cell lines.

Figure 1: Characterization of tigecycline resistance in TEX cells. (A, B) Growth and viability curves showing increased resistance in RTEX+TIG cells. (C) Cross-resistance to chloramphenicol. (D) Intracellular tigecycline concentrations remain similar between lines.

Metabolic and Structural Remodeling

Resistant cells underwent a profound metabolic shift, characterized by a complete shutdown of oxidative phosphorylation and a compensatory increase in glycolysis (the Warburg effect). This was evidenced by undetectable levels of mitochondrially encoded proteins Cox-1 and Cox-2, and a ~2-fold increase in lactate production. Structurally, mitochondria in RTEX+TIG cells appeared swollen with disrupted cristae under electron microscopy. Despite these changes, mitochondrial DNA (mtDNA) was not entirely lost, decreasing by approximately 58%.

HIF1α-Mediated Pseudohypoxia

Transcriptomic analysis revealed a significant upregulation of genes regulated by the HIF1α:HIF1β complex. This "pseudohypoxic" state, occurring under normal oxygen levels (normoxia), appears to drive the glycolytic shift. Upregulation of HIF1α mRNA and protein in RTEX+TIG cells was confirmed by Q-RTPCR and immunoblotting.

Reversibility and Metabolic Memory

A key finding was the reversibility of the metabolic phenotype. Upon drug withdrawal, mitochondrial protein levels and aerobic metabolism returned to baseline within a week. However, HIF1α levels remained elevated, suggesting a "molecular memory" that allows for rapid re-adaptation and re-establishment of the glycolytic phenotype upon re-exposure to the drug.

Discussion

This study demonstrates that AML cells can survive chronic mitochondrial stress through a reversible metabolic "shape-shifting" mechanism. By upregulating HIF1α, cells bypass the need for mitochondrial respiration. The persistence of elevated HIF1α even after drug removal suggests a primed state for resistance. These findings highlight potential therapeutic strategies, such as combining mitochondrial inhibitors with glycolysis inhibitors or HIF1α antagonists, to overcome or prevent resistance in AML.

Summary updated

Abstract

Recently, we demonstrated that the anti-bacterial agent tigecycline preferentially induces death in leukemia cells through the inhibition of mitochondrial protein synthesis. Here, we sought to understand mechanisms of resistance to tigecycline by establishing a leukemia cell line resistant to the drug. TEX leukemia cells were treated with increasing concentrations of tigecycline over 4 months and a population of cells resistant to tigecycline (RTEX+TIG) was selected. Compared to wild type cells, RTEX+TIG cells had undetectable levels of mitochondrially translated proteins Cox-1 and Cox-2, reduced oxygen consumption and increased rates of glycolysis. Moreover, RTEX+TIG cells were more sensitive to inhibitors of glycolysis and more resistant to hypoxia. By electron microscopy, RTEX+TIG cells had abnormally swollen mitochondria with irregular cristae structures. RNA sequencing demonstrated a significant over-representation of genes with binding sites for the HIF1α:HIF1β transcription factor complex in their promoters. Upregulation of HIF1α mRNA and protein in RTEX+TIG cells was confirmed by Q-RTPCR and immunoblotting. Strikingly, upon removal of tigecycline from RTEX+TIG cells, the cells re-established aerobic metabolism. Levels of Cox-1 and Cox-2, oxygen consumption, glycolysis, mitochondrial mass and mitochondrial membrane potential returned to wild type levels, but HIF1α remained elevated. However, upon re-treatment with tigecycline for 72 hours, the glycolytic phenotype was re-established. Thus, we have generated cells with a reversible metabolic phenotype by chronic treatment with an inhibitor of mitochondrial protein synthesis. These cells will provide insight into cellular adaptations used to cope with metabolic stress.
BibTeX
@inproceedings{jhas2013metabolic,
  author = {Bozhena Jhas and Shrivani Sriskanthadevan and Marko Škrtić and Mahadeo A. Sukhai and Véronique Voisin and Yulia Jitkova and Marcela Gronda and Rose Hurren and Rob C. Laister and Gary D. Bader and Mark D. Minden and Aaron D. Schimmer},
  title = {{Metabolic Adaptation to Chronic Inhibition of Mitochondrial Protein Synthesis in Acute Myeloid Leukemia Cells}},
  booktitle = {PLoS},
  year = {2013},
  doi = {10.1371/journal.pone.0058367},
}
Figure